https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47703 Wed 25 Jan 2023 10:34:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48569 Wed 22 Mar 2023 15:26:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13697 Wed 11 Apr 2018 16:44:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53703 Wed 10 Jan 2024 11:03:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29075 Tue 17 Sep 2019 15:21:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45311 Thu 27 Oct 2022 11:46:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32050 Thu 27 Jan 2022 15:58:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32180 .37 for interaction). Similarly, the treatment effects of low- vs standard-dose alteplase on function outcome (ordinal shift of the modified Rankin Scale) in Asians (odds ratio, 1.05; 95% CI, 0.90-1.22) was consistent with non-Asians (odds ratio, 0.93; 95% CI, 0.76-1.14) (P = .32 for interaction). There were generally consistent reductions in rates of symptomatic intracerebral hemorrhage with low-dose alteplase, although this reduction was not statistically significant by age, ethnicity, or severity. Conclusions and Relevance: This analysis found that the effects of low-dose alteplase were not clearly superior to the effects of standard-dose alteplase on death or disability in key demographic subgroups of patients with AIS. Further investigation is required to identify patients with AIS who may benefit from low-dose alteplase. Trial Resgistration: clinicaltrials.gov Identifier: NCT01422616.]]> Thu 27 Jan 2022 15:56:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43260 Thu 15 Sep 2022 11:06:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30831 Thu 14 Apr 2022 11:05:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19005 0.4) was reported for 16 of 20 general initiatives with observed percentage agreement ranging from 82.1%-100.0%. The majority of participants indicated the Web-based survey was easy to complete (97.9%, 531/543) and comprehensive (93.1%, 505/543). Participants also reported the interactive relative prioritization exercise was easy to complete (97.0%, 189/195) and helped them to decide which initiatives were of most importance (84.6%, 165/195). Average completion time was 8.54 minutes (SD 3.91) and the Flesch-Kincaid reading level was 6.8. Overall, 84.6% (447/529) of participants indicated a willingness to complete a similar survey again. Conclusions: The Web-based Consumer Preferences Survey is sufficiently reliable and highly acceptable to patients. Based on completion times and reading level, this tool could be integrated in routine clinical practice and allows consumers to easily participate in quality evaluation. Results provide a comprehensive list of patient-prioritized initiatives for patients with major chronic conditions and delivers practice-ready evidence to guide improvements in patient-centered care.]]> Sat 24 Mar 2018 08:05:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22149 Sat 24 Mar 2018 07:16:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52857 Mon 30 Oct 2023 10:00:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49695 Mon 29 May 2023 12:46:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48109 Mon 27 Feb 2023 15:22:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44147 Mon 10 Oct 2022 09:17:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41084 Fri 22 Jul 2022 17:11:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41732 Fri 12 Aug 2022 10:46:17 AEST ]]>